MX2009002054A - Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. - Google Patents

Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.

Info

Publication number
MX2009002054A
MX2009002054A MX2009002054A MX2009002054A MX2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A MX 2009002054 A MX2009002054 A MX 2009002054A
Authority
MX
Mexico
Prior art keywords
angiogenesis
associated diseases
methods
treating
composition
Prior art date
Application number
MX2009002054A
Other languages
English (en)
Inventor
Neil P Desai
Vuong Trieu
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2009002054A publication Critical patent/MX2009002054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invención proporciona métodos para inhibir la angiogénesis en un individuo mediante la administración de una composición (como una proteína contenida en la composición) que comprende el dímero de colchicina o tiocolchicina. La composición está presente en una cantidad efectiva para la inhibición de angiogénesis, pero en algunas modalidades es insuficiente para inducir una citotoxicidad significativa en el individuo. Los métodos descritos aquí son útiles para el tratamiento contra enfermedades asociadas con la angiogénesis, como degeneración macular relacionada con la edad, retinopatía diabética, artritis reumática, psoriasis y cáncer.
MX2009002054A 2006-08-31 2006-08-31 Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis. MX2009002054A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/034365 WO2008027055A1 (en) 2006-08-31 2006-08-31 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases

Publications (1)

Publication Number Publication Date
MX2009002054A true MX2009002054A (es) 2009-05-01

Family

ID=37763804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002054A MX2009002054A (es) 2006-08-31 2006-08-31 Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.

Country Status (9)

Country Link
EP (1) EP2056812A1 (es)
JP (1) JP2010502603A (es)
CN (1) CN101568332A (es)
AU (1) AU2006347740A1 (es)
BR (1) BRPI0622006A2 (es)
CA (1) CA2662140A1 (es)
IL (1) IL197276A0 (es)
MX (1) MX2009002054A (es)
WO (1) WO2008027055A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CN101291659A (zh) 2005-08-31 2008-10-22 阿布拉科斯生物科学有限公司 包含水难溶性药剂和抗微生物剂的组合物
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
PL2131821T3 (pl) 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
MY175260A (en) 2009-04-15 2020-06-17 Abraxis Bioscience Llc Prion free nanoparticle compositions and methods of making thereof
EP2515930A4 (en) * 2009-12-21 2013-04-10 Tty Biopharm Co Ltd METHODS AND COMPOSITIONS BASED ON REDUCED MET PHOSPHORYLATION BY CHEMOTAXIN 2 DERIVED FROM LEUKOCYTE CELLS IN TUMOR CELLS
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
CN107158389A (zh) 2010-03-29 2017-09-15 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
JP6031718B2 (ja) * 2011-09-20 2016-11-30 国立大学法人 熊本大学 リポ蛋白を用いたα２−マクログロブリンの神経保護抑制効果抑止剤及び眼科用組成物
ES2746057T3 (es) 2011-12-14 2020-03-04 Abraxis Bioscience Llc Uso de excipientes poliméricos para liofilización o congelación de partículas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
AU2014236802B2 (en) 2013-03-14 2019-01-03 Abraxis Bioscience, Llc Methods of treating bladder cancer
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
AU2019239953A1 (en) 2018-03-20 2020-10-15 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
ES2685436T3 (es) * 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
KR20180098702A (ko) * 2002-12-09 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US6825236B2 (en) * 2003-04-14 2004-11-30 California Pacific Medical Center Colchicine derivatives
ITMI20040164A1 (it) * 2004-02-03 2004-05-03 Indena Spa Derivati di n.deacetiltiocolchicina loro uso e formulazioni farmaceutiche che li contengono
CA3054535A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy

Also Published As

Publication number Publication date
JP2010502603A (ja) 2010-01-28
CA2662140A1 (en) 2008-03-06
CN101568332A (zh) 2009-10-28
AU2006347740A1 (en) 2008-03-06
EP2056812A1 (en) 2009-05-13
WO2008027055A1 (en) 2008-03-06
BRPI0622006A2 (pt) 2011-12-20
IL197276A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
MY155961A (en) Chemical compounds 251
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
TW200626576A (en) Bicyclic amides as kinase inhibitors
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
IN2012DN02018A (es)
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
IN2014MN00139A (es)
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
MX347225B (es) Metodos de tratamiento contra el cancer pancreatico.
ATE401088T1 (de) Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
UY29161A1 (es) Nuevos heterociclos
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
TW200740808A (en) Inhibiteurs de proteines kinases
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal